- Home
- ESRT vs CDNA Comparison
ESRT vs CDNA Comparison
Compare ESRT & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESRT
- CDNA
- Stock Information
- Founded
- ESRT 2011
- CDNA 1998
- Country
- ESRT United States
- CDNA United States
- Employees
- ESRT N/A
- CDNA N/A
- Industry
- ESRT Real Estate Investment Trusts
- CDNA Medical Specialities
- Sector
- ESRT Real Estate
- CDNA Health Care
- Exchange
- ESRT Nasdaq
- CDNA Nasdaq
- Market Cap
- ESRT 1.2B
- CDNA 1.0B
- IPO Year
- ESRT 2013
- CDNA 2014
- Fundamental
- Price
- ESRT $8.03
- CDNA $19.21
- Analyst Decision
- ESRT Hold
- CDNA Buy
- Analyst Count
- ESRT 2
- CDNA 6
- Target Price
- ESRT $10.65
- CDNA $30.33
- AVG Volume (30 Days)
- ESRT 2.1M
- CDNA 946.8K
- Earning Date
- ESRT 07-23-2025
- CDNA 07-30-2025
- Dividend Yield
- ESRT 1.75%
- CDNA N/A
- EPS Growth
- ESRT 2.67
- CDNA N/A
- EPS
- ESRT 0.30
- CDNA 1.07
- Revenue
- ESRT $762,039,000.00
- CDNA $346,421,000.00
- Revenue This Year
- ESRT $3.70
- CDNA $13.31
- Revenue Next Year
- ESRT $2.56
- CDNA $15.46
- P/E Ratio
- ESRT $26.35
- CDNA $17.88
- Revenue Growth
- ESRT 0.78
- CDNA 25.92
- 52 Week Low
- ESRT $6.56
- CDNA $13.81
- 52 Week High
- ESRT $11.62
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- ESRT 48.44
- CDNA 57.48
- Support Level
- ESRT $7.47
- CDNA $18.64
- Resistance Level
- ESRT $8.76
- CDNA $19.44
- Average True Range (ATR)
- ESRT 0.27
- CDNA 0.75
- MACD
- ESRT -0.09
- CDNA -0.05
- Stochastic Oscillator
- ESRT 43.41
- CDNA 46.86
About ESRT Empire State Realty Trust Inc.
Empire State Realty Trust operates as a pure-play greater New York and Manhattan-focused REIT, featuring its landmark Empire State Building office and observation deck. The company owns and operates around 8.5 million square feet of office space, about 80% of which is located in Manhattan.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.